Industry-University Cooperation Foundation Hanyang University

Korea Institute of Science and Technology

Hyundai Motor Company

Kia Motors Corporation

Chung Ang University Industry Academic Cooperation

Kyung Chang Industrial Co., Ltd.

Iucf-hyu

Yong-Hee Kim

Seo Young Jeong

Kwang-Suk Lim

Yoon Sung Song

Tae-Hwan Kim

Ick Chan Kwon

Ick-Chan Kwon

Kuiwon Choi

Jae Bong Choi

Kyu-Jung Kim

Chul-Su Yang

Ean-Soo Cho

Young-Wook Won

Kyu Back Lee

Jae Ho Koh

Seok-Beom Yong

Min-Keun Kwon

Hyung Jin Kim

Myung-Lyul Na

Yoonsung Song

Jang-Kyoung Kim

Jee Young Chung

Jee-Young Chung

Hyun-Lin Lee

Sungsin Jo

Qurrat Ui Ain

So Mi Kim

Ye-Ram Kim

Jang Kyoung Kim

Jang-Kyung Kim

Buom-Yong Ryu

The present invention relates to a method for differentiating hair follicle cells into germline stem cells, germline stem cells differentiated by the method, and use of the same germline stem cells. A method of differentiating hair follicle cells into germline stem cells according to the present invention can differentiate hair follicle cells into germline stem cells using culture conditions only, without genetic modification. Capable of inducing differentiation of cells of specific individual types, such as hair follicle cells, into cells of different types such as germline cells, the present invention is therefore expected to be usefully used for the understanding of reproductive biology and the clinical application thereof.

Method of transdifferentiating hair follicle stem cells into sperm stem cells

The present disclosure relates to: an adipocyte-targeting non-viral gene delivery complex comprising a sh(FABP4+FABP5) dual plasmid vector; and treatment for obesity and obesity-induced metabolic syndromes by using the same and, more particularly, to a gene delivery complex comprising: an adipocyte-targeting sequence; a nine-arginine (R9) peptide; and a dual plasmid vector comprising a gene for treatment of obesity and obesity-induced metabolic syndromes, wherein the gene for treatment of obesity and obesity-induced metabolic syndromes is a base sequence inhibiting the expression of a FABP4 gene and a FABP5 gene. According to the present disclosure, in order to treat obesity-related diseases, a dual plasmid vector capable of simultaneously inhibiting the FABP4 and FABP5 genes is produced, and this vector is bound to a predetermined delivery system that specifically delivers the vector into adipocytes so as to provide a gene delivery complex. In this way, it is possible to achieve an excellent therapeutic effect on obesity which targets only adipocytes without cytotoxicity.

Adipocyte-targeting non-viral gene delivery complex comprising dual plasmid vector

The present invention relates to a visceral adipose tissue macrophage-targeted non-viral gene/carrier complex for preventing and treating obesity-induced type II diabetes. More specifically, the gene/carrier complex according to the present invention delivers a therapeutic gene in a stable manner in a case of being injected into the body with the visceral adipose tissue macrophages being targeted, and thus exhibits an excellent inhibitory effect against TACE, which allows the gene/carrier complex to be applied for prevention or treatment of obesity-induced type II diabetes.

Visceral adipose tissue macrophage-targeted gene/carrier complex for preventing or treating obesity-induced type II diabetes

Disclosed is a gene/carrier complex for preventing or treating inflammatory diseases, including tumor necrosis factor-&#x3b1; converting enzyme (TNF-&#x3b1; converting enzyme, TACE) shRNA and a nonviral gene carrier, wherein the nonviral gene carrier includes an acetate of disulfide-linked poly(oligo-arginine) or a TFA salt of poly(oligo-aspartic acid)poly(oligo-arginine).

Gene/carrier complex for preventing or treating inflammatory diseases

The present invention relates to a parenteral bioactive substance delivery composition and a bioactive substance carrier using a micelle based on low molecular weight methyl cellulose with a weight average molecular weight of 6 to 9.5 kDa. The low molecular weight methyl cellulose with a weight average molecular weight of 6 to 9.5 kDa resolves a problem of excretion to outside of the body to improve safety and form a micelle to solubilize poorly soluble bioactive substances, and thus is very useful for sustained release parenteral bioactive substance delivery.

Parenteral bioactive substance delivery composition based on low molecular weight methyl cellulose

A Transmission Gear Shift (TGS) cable socket including a rubber damper to couple a TGS lever and an outer cable to each other so a manipulation force of the TGS lever is transmitted to a transmission through an inner cable disposed in the outer cable, may include the rubber damper to damp vibration transmitted from the outer cable, a steel cup disposed coaxially with the rubber damper, the steel cup having a first end disposed in the rubber damper, and a second end protruding from the rubber damper and coupled to the outer cable, and a guide pipe disposed coaxially with the rubber damper, the guide pipe including a first end disposed in the rubber damper at a position spaced apart from the steel cup, and a second end protruding from the rubber damper.

TGS cable socket including rubber damper and method of manufacturing the same

The present invention relates to a gene delivery system for targeting adipocytes and a treatment system for obesity and obesity-derived metabolic syndromes using the same and, more particularly, to a non-viral gene delivery system which directly targets a differentiated obesity (mature) adipocyte and contains an adipocyte targeting sequence (ATS)-arginine (R9) peptide.

Adipocyte-targeting non-viral gene delivery system

The present invention relates to a gene delivery system which improves siRNA delivery and the in vivo systemic circulation efficiency thereof More particularly, the present invention is a siRNA gene delivery system for systemic circulation based on polyethylene glycol (PEG) and an arginine 9 (R9) peptide.

Short interference RNA gene delivery system for systemic circulation

The present invention relates to a parenteral drug delivery carrier and a drug delivery system that use a thermosensitive gel based on methyl cellulose alone as a low molecular weight polysaccharide without a salting-out salt. The single use of the low molecular weight methyl cellulose as a natural polymer increases the biocompatibility and biodegradability of the drug delivery system. Therefore, the drug delivery system is suitable for use in the preparation of a sustained release composition for parenteral drug delivery.

Low molecular weight methyl cellulose-based parenteral drug delivery system

A method of manufacturing a porous matrix-type drug delivery system is provided. It comprises the steps of: dispersing, stirring, and emulsifying an aqueous solution of a drug in an organic solvent having a polymer compound and a surface active agent solved therein; thereafter forming it into a desirable matrix shape; lyophilizing or drying it at a low temperature or room temperature until the matrix surface is hardened; and drying it again in order to remove the water and the organic solvent.

Method of manufacturing porous matrix-type controlled release systems using emulsion technique

Preparation method for biodegradable polymeric microspheres using

Growing community of inventors

Seoul, South Korea

Yong-Hee Kim